Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.76 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.76 |
| ▸ | THRB | P10828 | 2/20 | 0.76 |
| ▸ | MAPT | P10636 | 1/20 | 0.76 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.76 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.76 |
| ▸ | GABBR2 | O75899 | 7/20 | 0.54 |
| ▸ | GABBR1 | Q9UBS5 | 7/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | DRD3 | P35462 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1893272 | 1.00 | LMNA (0.76) | LMNACYP1A2THRBMAPTPMP22 | |
| SCHEMBL1887532 | 1.00 | LMNA (0.76) | LMNACYP1A2THRBMAPTPMP22 | |
| Phaclofen SCHEMBL339995 | 0.86 | LMNA (1.00) | LMNACYP1A2THRBMAPTPMP22 | |
| Phaclofen SCHEMBL10343565 | 0.85 | LMNA (0.97) | LMNACYP1A2THRBMAPTPMP22 | |
| SCHEMBL6358532 | 0.83 | GABBR2 (0.53) | LMNACYP1A2THRBMAPTPMP22 | |
| SCHEMBL6350896 | 0.81 | LMNA (0.68) | LMNACYP1A2THRBMAPTPMP22 | |
| SCHEMBL6361790 | 0.78 | LMNA (0.62) | LMNACYP1A2THRBMAPTPMP22 | |
| Phaclofen SCHEMBL10343564 | 0.78 | LMNA (0.68) | LMNACYP1A2THRBMAPTPMP22 | |
| SCHEMBL9417082 | 0.76 | LMNA (0.56) | LMNACYP1A2THRBMAPTPMP22 | |
| SCHEMBL10507284 | 0.75 | GABBR2 (0.64) | LMNACYP1A2THRBMAPTPMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7494985-B2 | Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use | XENOPORT, INC. (US) | 2009-02-24 | — | — | US | claimed |
| US-20060111325-A1 | Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use | XENOPORT, INC. | 2006-05-25 | — | — | US | claimed |
| WO-2006050472-A2 | ACYLOXYALKYL CARBAMATE PRODRUGS OF 3-AMINOPROPYLPHOSPHONOUS AND -PHOSPHINIC ACIDS | XENOPORT, INC. (US) | 2006-05-11 | — | — | WO | claimed |
| EP-1372620-A2 | METHODS FOR RESTORING COGNITIVE FUNCTION FOLLOWING SYSTEMIC STRESS | Saegis Pharmaceuticals (US) | 2004-01-02 | — | — | EP | claimed |
| US-20020187977-A1 | Methods for restoring cognitive function following systemic stress | SAEGIS PHARMACEUTICALS, INC. | 2002-12-12 | — | — | US | claimed |
| WO-2002074293-A2 | METHODS FOR RESTORING COGNITIVE FUNCTION FOLLOWING SYSTEMIC STRESS | SAEGIS PHARMACEUTICALS INC (US) | 2002-09-26 | — | — | WO | claimed |
| EP-0463560-B1 | New antiepileptic agents | CIBA GEIGY AG (CH) | 1995-10-25 | — | — | EP | claimed |
| US-5300679-A | Antagonists to 4-aminobutyric acid | CIBA-GEIGY CORPORATION (US) | 1994-04-05 | — | — | US | claimed |
| EP-0463560-A1 | New antiepileptic agents | CIBA-GEIGY AG (CH) | 1992-01-02 | — | — | EP | claimed |
| US-7935686-B2 | Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use | XENOPORT, INC. (US) | 2011-05-03 | — | — | US | disclosed |
| US-20090124582-A1 | Acyloxyalkyl Carbamate Prodrugs, Methods of Synthesis, and Use | XENOPORT, INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-7494985-B2 | Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use | XENOPORT, INC. (US) | 2009-02-24 | — | — | US | disclosed |
| US-20060111325-A1 | Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use | XENOPORT, INC. | 2006-05-25 | — | — | US | disclosed |
| WO-2006050472-A2 | ACYLOXYALKYL CARBAMATE PRODRUGS OF 3-AMINOPROPYLPHOSPHONOUS AND -PHOSPHINIC ACIDS | XENOPORT, INC. (US) | 2006-05-11 | — | — | WO | disclosed |
| WO-2002074293-A2 | METHODS FOR RESTORING COGNITIVE FUNCTION FOLLOWING SYSTEMIC STRESS | SAEGIS PHARMACEUTICALS INC (US) | 2002-09-26 | — | — | WO | disclosed |
| US-5545631-A | GAMMA-AMINOBUTYRIC ACID ANTAGONIST; TREATS PETIT-MAL TYPE EPILEPSIES | CIBA-GEIGY CORPORATION (US) | 1996-08-13 | — | — | US | disclosed |
| EP-0463560-B1 | New antiepileptic agents | CIBA GEIGY AG (CH) | 1995-10-25 | — | — | EP | disclosed |
| US-5407922-A | GABA antagonists | CIBA-GEIGY CORPORATION (US) | 1995-04-18 | — | — | US | disclosed |
| US-5229379-A | Gamma-aminobutyric acid antagonists | CIBA-GEIGY CORPORATION (US) | 1993-07-20 | — | — | US | disclosed |
| EP-0463560-A1 | New antiepileptic agents | CIBA-GEIGY AG (CH) | 1992-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111325-A1 | Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use | APEH, AASDHPPT, AGPS | LMNA 3723/4885CYP1A2 2232/4885THRB 3156/4885 |
| US-20020187977-A1 | Methods for restoring cognitive function following systemic stress | CRH, BDNF, CHAT | LMNA 4098/4885CYP1A2 3291/4885THRB 2831/4885 |
| US-20090124582-A1 | Acyloxyalkyl Carbamate Prodrugs, Methods of Synthesis, and Use | APEH, AASDHPPT, AGPS | LMNA 3723/4885CYP1A2 2232/4885THRB 3156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.